Sunday, September 13, 2026
ExploreSearch
Finance Via News

Venture Capital & Private Equity

2 articles

Venture Capital Reclaims Mega-Round Leadership as Tiger Global, SoftBank Pull Back 95%

Venture Capital Reclaims Mega-Round Leadership as Tiger Global, SoftBank Pull Back 95%

Traditional venture capital firms have regained control of $50M+ financing rounds after Tiger Global Management and SoftBank Vision Fund cut their deal count by over 95% since 2021. The 2025 market saw 1,440 companies raise mega-rounds—half the 2021 total—with established VCs capitalizing on AI-wave opportunities while mega-investors retreat from overheated valuations.

ViaNews Editorial Team (Finance)•
Traditional VC Firms Reclaim 80% of $50M+ Deals as Tiger Global, SoftBank Retreat 95%

Traditional VC Firms Reclaim 80% of $50M+ Deals as Tiger Global, SoftBank Retreat 95%

Pure venture capital firms now lead 8 of 10 funding rounds above $50 million, reclaiming dominance from mega-investors who flooded the market in 2021. Tiger Global and SoftBank Vision Fund cut their deal activity by over 95% since peak deployment. The shift marks a return to specialized venture expertise as tourist capital exits.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com